In vitro activity of lomefloxacin, a difluorinated quinolone, compared with other antimicrobials
- PMID: 1889304
- DOI: 10.1159/000238850
In vitro activity of lomefloxacin, a difluorinated quinolone, compared with other antimicrobials
Abstract
A total of 3,144 clinical isolates from 3,011 consecutive patients were tested against lomefloxacin by the agar dilution method. They consisted of 1,380 isolates of Enterobacteriaceae, 527 pseudomonads, 47 Haemophilus influenzae, 53 Acinetobacter, 42 Brucella melitensis, 903 staphylococci and 192 strains of enterococci. In vitro activity of lomefloxacin was compared with ciprofloxacin, norfloxacin, beta-lactams and aminoglycosides. Over 98% of Enterobacteriaceae were susceptible to lomefloxacin with an MIC of 0.06-4.0 micrograms/ml. It also inhibited 93 and 85% clinical isolates of Pseudomonas aeruginosa and Xanthomonas maltophilia, respectively. All isolates of Haemophilus, Brucella and Staphylococcus aureus were susceptible to this fluoroquinolone. However, only 43% of the 192 strains of enterococci exhibited in vitro susceptibility. Lomefloxacin was found to be comparable to ciprofloxacin and norfloxacin in its in vitro activity, and superior to most penicillins, cephalosporins and aminoglycosides against both gram-negative and gram-positive bacteria except enterococci.
Similar articles
-
Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.J Antimicrob Chemother. 1997 Jun;39 Suppl B:29-34. doi: 10.1093/jac/39.suppl_2.29. J Antimicrob Chemother. 1997. PMID: 9222067
-
In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.Chemotherapy. 1992;38(2):99-106. doi: 10.1159/000238948. Chemotherapy. 1992. PMID: 1317282
-
In-vitro activity of lomefloxacin (SC-47111) and other quinolones.Infection. 1989 May-Jun;17(3):165-7. doi: 10.1007/BF01644019. Infection. 1989. PMID: 2737760
-
Synergy and antagonism of combinations with quinolones.Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):255-61. doi: 10.1007/BF01966998. Eur J Clin Microbiol Infect Dis. 1991. PMID: 1864285 Review.
-
Synergy of fluoroquinolones with other antimicrobial agents.Rev Infect Dis. 1989 Jul-Aug;11 Suppl 5:S1025-35. doi: 10.1093/clinids/11.supplement_5.s1025. Rev Infect Dis. 1989. PMID: 2505355 Review.
Cited by
-
Global prevalence and antibiotic resistance in clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis.Front Med (Lausanne). 2023 May 5;10:1163439. doi: 10.3389/fmed.2023.1163439. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37215718 Free PMC article.
-
Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.Antimicrob Agents Chemother. 2006 Jan;50(1):22-33. doi: 10.1128/AAC.50.1.22-33.2006. Antimicrob Agents Chemother. 2006. PMID: 16377662 Free PMC article. Review. No abstract available.
-
Prevalence of Brucella melitensis and Brucella abortus aminoglycoside-resistant isolates: a systematic review and meta-analysis.Braz J Microbiol. 2024 Mar;55(1):429-439. doi: 10.1007/s42770-023-01233-6. Epub 2024 Jan 16. Braz J Microbiol. 2024. PMID: 38228936 Free PMC article.
-
Unravelling the challenge of cotrimoxazole and rifampin resistance in B. melitensis and B. abortus: A systematic review and meta-analysis.PLoS Negl Trop Dis. 2024 Dec 2;18(12):e0012630. doi: 10.1371/journal.pntd.0012630. eCollection 2024 Dec. PLoS Negl Trop Dis. 2024. PMID: 39621798 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources